Chinese Co.'s US Unit Cut From Vitamin C Antitrust MDL

Law360, New York (January 10, 2012, 6:29 PM EST) -- A New York federal judge on Tuesday allowed a former U.S. subsidiary of a Chinese vitamin C manufacturer to exit a multidistrict litigation, finding there was no evidence that the unit was involved in a conspiracy to fix domestic prices of the vitamin.

The litigation accuses Jiangshan Pharmaceutical Co. Ltd., Hebei Welcome Pharmaceutical Co. Ltd., Northeast Pharmaceutical Group Co. Ltd. and Weisheng Pharmaceutical Co. Ltd. as well as Jiangshan subsidiary JSPC America Inc. of taking part in an illegal cartel to fix prices and limit supply...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.